NCT05143307
Long-Term Follow-Up Study of HIV-1 Infected Adults Who Received EBT-101
Enrolling by Invitation
PHASE1Ages 18+InterventionalExcision BioTherapeutics
~9 participants
Updated 2024-05-14 on ClinicalTrials.gov
What's tested:EBT-101
At a glance
Recruiting sites
0 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Long-term safety of EBT-101
Measured over 15 years
Conditions
Where it's being run
3 sites across 3 statesCalifornia1
Missouri1
New Jersey1
Study leadership
- William Kennedy, MD · STUDY_DIRECTOR · Excision BioTherapeutics
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Willing and able to provide written, signed informed consent
Participants who received the investigational study intervention EBT-101 in a parent study
What this trial measures
- Long-term safety of EBT-10115 years
Long-term safety of EBT-101 will be assessed based on incidence and severity of clinically significant adverse events (AEs) according to Division of AIDS (DAIDS) 2017 over 15 years